
Advocating for Medication for Opioid Use Disorder
Key Takeaways
- A coalition of 167 organizations pressed Senate leaders to advance the MAT Act to address an accelerating overdose crisis and reduce treatment stigma.
- Buprenorphine is positioned as a “gold standard” MOUD that supports sustained recovery and can decrease returns to illicit opioid use and incarceration.
The NCCHC and 166 national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine.
The National Commission on Correctional Health Care (NCCHC) and 166 national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine, an FDA-approved medication for opioid use disorder (OUD). They urged US Senate to pass the bipartisan
“In the midst of a deadly and accelerating overdose crisis, the MAT Act is a common-sense solution that will prevent overdoses, increase access to treatment, and reduce stigma,” the letter reads.
However, the
If passed, the MAT Act will eliminate the X-waiver and make buprenorphine more available and accessible for Americans with OUD.
The letter was sent to Majority Leader Chuck Schumer, Minority Leader Mitch McConnell, Chair Patty Murray, and Ranking Member Richard Burr on August 31, Overdose Awareness Day. The letter can be found
References
1. NCCHC Supports Access to MOUD. National Commission on Correctional Health Care. September 9, 2022. Accessed September 21, 2022.
2. The Mainstreaming Addiction Treatment Act (“MAT Act”, S. 445 / H.R. 1384). August 31, 2022. Accessed September 21, 2022.









